Heterogeneity of Unilateral Multiple Breast Cancer: Implications for Biomarker Testing

Main Article Content

Shanop Shuangshoti, MD
Ratchaya Sawatdee, MD
Anantnuch Sakapibunnan, MD
Wipawee Kittigowit, MD
Somruetai Shuangshoti, MD
Benjaporn Chaiwun, MD
Pichet Sampatanukul, MD
Apiwat Mutirangura, MD
Paul Scott Thorner, MD, PhD


This study was to re-examine the usefulness of biomarker assays in all multiple tumors in the same breast, and to evaluate the genetic heterogeneity of unilateral multiple breast carcinoma.

All of the cases met the criteria for synchronous multicentric breast carcinomas. Tumors were either 5 cm apart or within the different breast quadrants, with no identifiable connection between lesions, and were diagnosed at the same time for an individual patient.

In the present study, 32 tumors from 15 patients with synchronous unilateral breast cancer were immunostained for estrogen receptor (ER), progesterone receptor (PR), and HER-2, and also underwent microsatellite analysis using 10 polymorphic markers. The ER and PR expression profile was similar in all tumors from the same patient. Discordant HER-2 immunoreactivity was found and confirmed by HER-2 FISH test in one case, and heterogeneity in the microsatellite pattern was observed in 6 patients.

With the routinely-used biomarkers (ER, PR, and HER-2), heterogeneity was minimal, however, with more frequent differences noted at the genetic levels.


Download data is not yet available.

Article Details

How to Cite
Shuangshoti S, Sawatdee R, Sakapibunnan A, Kittigowit W, Shuangshoti S, Chaiwun B, Sampatanukul P, Mutirangura A, Thorner PS. Heterogeneity of Unilateral Multiple Breast Cancer: Implications for Biomarker Testing. BKK Med J [Internet]. 2014 Sep. 20 [cited 2023 Dec. 1];8(1):17. Available from: https://he02.tci-thaijo.org/index.php/bkkmedj/article/view/219720
Original Article